drugset / Trial / NCT00056381

Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

NCT00056381

Phase 1/2 Completed 25 enrolled Pfizer Vicuron Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count (neutropenia).

Timeline

Start
2003-07
Primary completion
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Anidulafungin Other / unclassified Intravenous

Indications